What Ignite Proteomics does

Ignite Proteomics is a Golden, Colorado-based biotechnology company founded in 2024 that operates a CLIA-certified clinical laboratory delivering functional proteomics testing for precision oncology. Its core technology is a proprietary Reverse Phase Protein Array (RPPA) platform that measures protein expression and activation state across 32 analytes — including key drug targets and signaling pathway markers — from limited samples (capable of detecting 100 analytes from ~10,000 cells) with up to 500X dynamic range. The company's flagship commercial product is a 32-analyte breast cancer assay that provides treating oncologists with biomarker results mapped to FDA-approved targeted therapies, including antibody drug conjugates and immunotherapies, operating under an established Medicare reimbursement pathway of approximately $2,200 per test.

The company operates two revenue streams. The first is clinical diagnostic testing sold via direct physician ordering using a streamlined one-page test request form to oncology practices across the United States. The second is BioPharma contract research, providing customized RPPA assay development, Laser Capture Microdissection (LCM) services, and bioinformatics reporting leveraging a validated analyte library of over 600 proteins and phosphoproteins across canonical oncology pathways. Ignite has accumulated clinical validation through I-SPY2, FAIRLANE, and Side Out 2 trial publications and a Dana-Farber-led peer-reviewed study in npj Precision Oncology (April 2026) demonstrating predictive value for trastuzumab deruxtecan outcomes.

Ignite was acquired by Aditxt, Inc. for $36 million in Series A-2 Convertible Preferred Stock in March 2026 and entered a definitive business combination agreement with SPAC Copley Acquisition Corp in June 2026 to form Ignite Proteomics Holdings, Inc., expected to list on the NYSE in the second half of 2026 at a pro forma enterprise value of approximately $150 million. Concurrent with the corporate restructuring, the company launched a 10,000-patient prospective oncology registry (enrollment beginning fall 2026) projected to generate approximately $13 million in revenue and to serve as the substrate for planned AI-enabled diagnostic and pharma companion diagnostic products. The company is led by CEO Jeffrey M. Busch.

Name

Ignite Proteomics

Legal name

Ignite Proteomics, LLC

Website

https://igniteproteomics.com

Company type

Private

Founded year

2024

Operating status

Operating

Headcount range

11–50 employees

Short description

Ignite Proteomics operates a CLIA-certified laboratory using proprietary Reverse Phase Protein Array (RPPA) technology to deliver functional proteomic testing for oncology therapy selection, serving treating oncologists via a 32-analyte breast cancer assay and BioPharma partners with custom assay and LCM services.

Ownership category

akta.pro rank

Product category

Precision Oncology Diagnostics

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413), Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Genomic & Multi-Omic Biomarkers (NGS panels, transcriptomics, proteomics, metabolomics) (HLAAAMAJ)

akta.pro secondary industries

Proteomics & Biomarker Analytical Testing (HLAGADAG), Proteomics & Mass Spectrometry Services (HLAGANAB), Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI)

Keywords

• Functional proteomics
• Precision oncology diagnostics
• Cancer biomarker assays
• Clinical laboratory services
• Protein array analysis

Headquarters

HQ city

Golden

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Clinical Diagnostic Testing: Revenue generated from CLIA-certified laboratory testing services for precision oncology. Medicare reimbursement pathway established at approximately $2,200 per test. Testing focuses on breast cancer with expansion planned into additional tumor types.
2. Oncology Registry Data Services: Revenue from prospective oncology registry enrolling up to 10,000 patients, projected to generate approximately $13 million over the course of the agreement. Registry captures protein profiles, therapy selections, and real-world clinical outcomes to support future diagnostic tool development and pharma collaborations.
3. BioPharma Research Services: Customized assay development and testing services for pharmaceutical company drug development programs. Services include LCM and RPPA analysis for therapeutic development in oncology and immuno-oncology from discovery through clinical trials.

Pricing tiers

Go-to-market motion2 records

Distribution channels2 records

Marketing channels5 records

Core offering

Ignite Proteomics operates a CLIA-certified laboratory that performs a proprietary 32-analyte Reverse Phase Protein Array (RPPA) assay for advanced breast cancer, generating physician reports that map protein expression and activation levels to FDA-approved drug options. The company also provides contract research services to pharmaceutical partners, offering Laser Capture Microdissection (LCM) and RPPA-based proteomic analysis from discovery through clinical trials, supported by a library of over 600 validated protein and phosphoprotein targets.

Product overview

Ignite Proteomics offers a precision oncology platform centered on its proprietary Reverse Phase Protein Array (RPPA) technology. The core offering is a 32-analyte breast cancer assay that operates through a CLIA-certified laboratory with established Medicare reimbursement (approximately $2,200 per test), generating physician reports that link biomarker results to FDA-approved treatment options. The BioPharma services module provides contract research capabilities including Laser Capture Microdissection and RPPA services, supported by an analyte library of over 600 validated protein/phosphoprotein targets. The company is also developing AI-enabled diagnostic optimization capabilities planned for future release through its oncology registry initiative.

Differentiator

Problem solved

Functional benefit

Products and services

• 32-Analyte Breast Cancer Assay Proprietary Reverse Phase Protein Array (RPPA) assay measuring 32 biomarkers for advanced breast cancer that provides treating physicians with actionable treatment recommendations tied to FDA-approved drugs based on protein expression and activation levels. Operated through a CLIA-certified laboratory.
• BioPharma Research Services Contract research services for pharmaceutical partners including Laser Capture Microdissection (LCM) and Reverse Phase Protein Microarray (RPPA) services, with access to over 600 validated protein and phosphoprotein targets and customized bioinformatics reporting for drug development from discovery through clinical trials.

Quantifiable outcome

• Identified TOPO1 expression in HER2-negative patients where conventional HER2 IHC showed limited predictive value
• +3 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Two partnerships are on record, tiered core.

• Established Clinical Network of Oncology PracticescoreStrategic or Co-development Partner · 8 June 2026Ignite Proteomics partnered with an established clinical network of oncology practices for the 10,000-patient prospective oncology registry. Enrollment expected to begin fall 2026 through this network, generating approximately $13 million in revenue. The registry will capture RPPA-measured protein and phosphoprotein profiles, therapy selections, and real-world clinical outcomes to build an evidence base supporting future diagnostic tools and pharma collaborations.
• Dana-Farber Cancer InstitutecoreStrategic or Co-development Partner · 20 April 2026Dana-Farber Cancer Institute led a peer-reviewed study published in npj Precision Oncology demonstrating predictive value of Ignite's RPPA platform for patient outcomes in metastatic breast cancer patients treated with trastuzumab deruxtecan (Enhertu). The study found that while conventional HER2 immunohistochemistry showed limited predictive value, Ignite's platform identified TOPO1 expression in certain HER2-negative patients, suggesting potential for measuring tumor biology beyond HER2 expression alone.

Scale indicators5 records

Recent moves8 records

Expansion highlights6 records

Direct peers

• Caris Life Sciences: Caris offers MI Profile and Caris Assure for molecular profiling across DNA, RNA, and protein to guide oncology therapy selection. It competes head-to-head with Ignite for oncologist adoption and biopharma companion Dx partnerships, including protein-level readouts.
• Natera: Natera is a molecular diagnostics company with an oncology franchise (Signatera, Empower, Vantage) that uses tissue- and blood-based molecular profiling to guide treatment decisions in cancer. Like Ignite, it sells actionable biomarker tests to oncologists and biopharma partners with established reimbursement.
• Biognosys: Biognosys is a proteomics CRO using mass spectrometry-based discovery and targeted proteomics (SpectroDive, PQ500) for biopharma drug development. It is the closest technical analogue to Ignite's BioPharma RPPA services business, both selling pathway-level proteomics to pharma.

Broad incumbents

• Guardant Health: Guardant360 and Guardant Infinity provide liquid-biopsy NGS profiling for advanced cancer therapy selection, with established Medicare coverage and biopharma partnerships. It is a larger, well-capitalized incumbent that Ignite must compete against for oncologist ordering share.
• Foundation Medicine: FoundationOne CDx and FoundationOne Liquid CDx are widely adopted comprehensive genomic profiling tests for oncology therapy selection with FDA approval as companion diagnostics and broad payer coverage. As a Roche subsidiary, it sets the standard Ignite must differentiate against on clinical utility.
• NeoGenomics: NeoGenomics operates a large CLIA-certified oncology lab offering a broad menu of molecular and protein-based tests (including IHC, FISH, and NGS) to community oncologists. It is a scaled incumbent with overlapping customer accounts and reimbursement infrastructure.
• Exact Sciences: Exact Sciences (Cologuard, Oncotype, Previu) is a major molecular diagnostics company expanding into oncology therapy selection and MRD. Its scale, payer relationships, and biopharma collaborations make it a relevant broad incumbent against which Ignite must differentiate on functional proteomics.

Emerging players

• Olink: Olink provides high-throughput targeted proteomics (Explore, Target, Reveal platforms) for biomarker discovery and biopharma applications, including oncology. Its technology overlaps with Ignite's analyte library approach and serves the same biopharma customer segment.
• Tempus: Tempus combines multi-omic profiling (DNA, RNA, proteomics via xR, imaging) with AI-driven analytics for oncology therapy selection and biopharma R&D. Its proteomics initiatives are directly comparable to Ignite's RPPA-based functional readouts and target the same oncology and biopharma customers.
• Personalis: Personalis provides ultra-sensitive cancer genomics (NeXT Personal) for MRD and therapy selection, and partners with biopharma on companion Dx. It is comparable in offering comprehensive molecular profiling services to oncologists and pharma, though currently more DNA/RNA-centric than Ignite.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/ignite-proteomics

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ignite Proteomics